(Press-News.org) New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.
Presenting the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A, Professor Jean-Charles Soria told the 2013 European Cancer Congress (ECC2013) [1] today (Sunday): "This is the first study to suggest a potential relationship between smoking history and response to inhibiting the PD-L1/PD-1 pathway – a pathway that is instrumental in enabling cancer cells to escape detection by the immune system. In this study, 26% of smokers responded to treatment, whereas only 10% of never-smokers responded. The fact that smokers seemed to respond better is great news for lung cancer patients, because the majority of them are former or current smokers. Most advances in lung cancer over the last five years have mainly focused in never or light smokers. While the data are preliminary, the trend is potentially promising."
Lung cancer, which is usually caused by smoking, is extremely difficult to treat successfully and once it has started to spread (metastasise) to other parts of the body it is incurable. The programmed death 1 protein PD-1 and its signalling molecule (or ligand) PD-L1 prevent the body's immune system from attacking and killing cancer cells and this allows the cancer to spread. However, the anti-PD-L1 monoclonal antibody, MPDL3280A, works by blocking the interaction between PD-L1 and the immune system, thereby boosting a patient's anti-cancer immune response.
Prof Soria, Director of the Site de Recherche Intégrée sur le Cancer (SIRIC) Socrate project at the Institut Gustave Roussy, France, and his colleagues are enrolling patients with metastatic non-small cell lung cancer (NSCLC) who have failed to respond to chemotherapy into the international trial. They are treating them with an intravenous infusion of MPDL3280A once every three weeks. At the ECC2013 congress, they presented efficacy data for 53 NSCLC patients and safety data for 85 NSCLC patients – the largest group of patients to be treated with anti-PD-L1 blockade to date.
"We hypothesised that smoking was associated with tumours that harbour more genetic mutations and, therefore, the immune systems of these patients might be more likely to respond and attack the tumours once PD-L1 had been blocked," explained Prof Soria. "Our results show that this is likely to be the case because more smokers than non-smokers had a partial response to the therapy."
Although the best results were seen in smokers or former smokers, Prof Soria said that the anti-PD-L1 antibody was also an important strategy for non-smokers. "Some of them benefited from this compound as well."
Among the responding patients, treatment duration ranged from 170 to 534 days. "We observed sustained and rapid responses," said Prof Soria. "Some patients responded to the drug within six weeks, and we can now report for the first time that the median average time to first response is 11.9 weeks." [2]
In addition, the researchers also discovered that there was an increase in response rates in patients who had tumours that had high numbers of cells expressing PD-L1. Patients with higher levels of PD-L1 expression were more likely to respond to anti-PD-L1 blockade than patients with lower levels of PD-L1 expression. Using an immunohistochemistry (IHC) [3] scoring system for PD-L1, with a scale for IHC expression ranging from 0 to 3, patients with IHC 3 had a response rate of 83% and patients with IHC 2/3 had a response rate of 46%.
"The higher the percentage of PD-L1 staining in a tumour, the better the probability a patient will have an objective response with the PD-L1 antibody," explained Prof Soria. [4]
He concluded: "Our results so far demonstrate that the compound is capable of producing striking and durable responses in non-small cell lung cancer patients with metastatic disease who have failed to respond to previous chemotherapy. The study defines a novel approach to identifying the patients most likely to respond to treatment and identifies potential association between smoking and responses to MPDL3280A. A new therapy, with few serious adverse side-effects, that is easy to use – one intravenous infusion every three weeks – and a robust clinical activity as a single agent should soon be available."
The large phase I expansion trial is continuing, but larger phase II/III trials of the drug have already started.
ECCO President, Professor Cornelis van de Velde, commented: "This is an extremely important study for patients with non-small cell lung cancer for whom there are few treatment options that make much impact on their disease. Hundreds of millions of Euros have been spent chasing the dream of immunotherapy for lung cancer patients, but with zero results. These early findings on the effect of the anti-PD-L1 monoclonal antibody, MPDL3280A, suggest that it has the potential to open new therapeutic approaches, particularly for smokers and former smokers."
###
[1] The 2013 European Cancer Congress is the 17th congress of the European CanCer Organisation (ECCO), the 38th congress of the European Society for Medical Oncology (ESMO) and the 32nd congress of European Society for Therapeutic Radiology and Oncology (ESTRO).
[2] The median average is the number separating the higher half of the patient response time from the lower half i.e. the middle number.
[3] Immunohistochemistry is the process of detecting particular proteins (or antigens) in cells in tissue samples in the laboratory.
[4] An objective response is where a tumour shows either a complete or a partial response to treatment.
[5] This study is funded by Genentech Inc.
Promising results for new antibody drug in non-small cell lung cancer patients: Smokers respond well
2013-09-30
ELSE PRESS RELEASES FROM THIS DATE:
Identifying the disease-causing mechanisms in cancers with unknown primary site improves treatment
2013-09-30
Identifying the molecular profile of a tumour where the primary site is unknown is crucial to the choice of treatment, the 2013 European Cancer Congress (ECC2013) [1], will hear on Monday. In up to five percent of all cancers, the site of the primary tumour is unknown and the disease is not diagnosed until it is at an advanced stage, when the cancer has metastasised (spread to other parts of the body). Until recently, the choice of treatment has been based on efforts to find biomarkers that could indicate the site of origin, but now a team of researchers has succeeded in ...
Organized screening for prostate cancer does more harm than good
2013-09-30
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research to be presented on Monday by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC2013) [1].
Prof Boniol, Research Director at the International Prevention Research Institute (iPRI) and Professor at the Strathclyde Institute for Global Public Health at iPRI, Lyon, France, will ...
Leukemia cells are addicted to a healthy gene
2013-09-30
What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an internal "balance of terror" to keep going. When one version of a certain gene is mutated, it becomes a cancer-promoting gene – an oncogene. But the new findings show that the second, normal version of the gene, which functions alongside the mutation, is what keeps the cells both cancerous and alive, able to continue forging their destructive pathway in ...
Eilat's corals stand better chance of resilience than other sites
2013-09-30
Jerusalem, Sept. 29, 2013 – Israel's southern Red Sea resort of Eilat, one of whose prime attractions is its colorful and multi-shaped underwater coral reefs, may have a clear advantage in the future over rival coral-viewing sites around the world, scientists at the Hebrew University of Jerusalem and Bar-Ilan University have found.
Coral reefs, earth's richest and most diverse ecosystem, are deteriorating rapidly. One of the most devastating causes for that deterioration is coral bleaching, which typically occurs when seawater temperatures exceed the local summer maximum ...
New approaches to testing cancer drugs needed -- ESMO press commentary
2013-09-30
Lugano, Switzerland, 28th September -- Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalised medicine to patients across Europe, says the European Society for Medical Oncology.
It has become clear in recent years that each patient's cancer has individual characteristics that are potentially amenable to "personalised" treatments that target those characteristics. But there is still a great deal of work to be done to ensure patients benefit ...
A review concerning relationships and independence of human number, time and space processing
2013-09-30
Perception of NTS are basic cognitive processes for humans to interact with their environment. Whether a common magnitude system exits for NTS processing is such an important question to investigate. Following and guided by previous researchers, Dr. Yalin Chen and Chang Liu, from the Laboratory of Cognitive Neuroscience and the School of Psychology, Nanjing Normal University, China, reviewed present evidence and provided some comments concerning this question. Their work, entitled "Relationships and independence of human number, time, and space processing", was published ...
Climate change: Fast out of the gate, slow to the finish the gate
2013-09-30
Washington, D.C.— A great deal of research has focused on the amount of global warming resulting from increased greenhouse gas concentrations. But there has been relatively little study of the pace of the change following these increases. A new study by Carnegie's Ken Caldeira and Nathan Myhrvold of Intellectual Ventures concludes that about half of the warming occurs within the first 10 years after an instantaneous step increase in atmospheric CO2 concentration, but about one-quarter of the warming occurs more than a century after the step increase. Their work is published ...
Young children recognize cigarette brands in developing countries with most smokers
2013-09-30
Nearly two-thirds of young children in low- and middle-income countries can identify cigarette brand logos, according to a study from researchers at the University of Maryland School of Public Health (UMD SPH) and the Johns Hopkins Bloomberg School of Public Health (JHSPH).
The study, published in the journal Pediatrics, examined the reach of tobacco and cigarette marketing among some of the world's most vulnerable populations, sampling five and six year-old children from Brazil, China, India, Nigeria, Pakistan and Russia. These countries were selected because they have ...
Beyond the little blue pill: scientists develop compound that may treat priapism
2013-09-30
Bethesda, MD -- It's not the little blue pill famous for helping men get big results, but for those who need it, the outcome might be even more significant. A new research report published online in The FASEB Journal, offers hope to men who experience priapism. This condition, which is often seen in men with sickle cell disease, causes erections lasting so long that they cause permanent damage to the penis. Specifically, a compound, called "C6'" offered mice -- with and without sickle cell disease -- relief by normalizing nitric oxide levels in penile blood. In addition ...
Niacin, the fountain of youth
2013-09-30
Who would not want to live a long and healthy life? A freely available food supplement could help in this respect, scientists from ETH Zurich have demonstrated in roundworms. Vitamin B3 – also known as niacin – and its metabolite nicotinamide in the worms' diet caused them to live for about one tenth longer than usual.
As an international team of researchers headed by Michael Ristow, a professor of energy metabolism, has now experimentally demonstrated, niacin and nicotinamide take effect by promoting formation of so-called free radicals. "In roundworms, these reactive ...